Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00429299
Status:
COMPLETED
Last Update Posted:
2016-03-22
First Post:
2007-01-29
Brief Title:
Neoadjuvant Study With Chemotherapy Lapatinib And Trastuzumab In Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2 Primary Breast Cancer A Randomized Phase IIb Study With Biomarker Evaluation
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHERLOB
Brief Summary:
Evaluate the activity of Trastuzumab Lapatinib and a combination of both agents with chemotherapy in the preoperative neoadjuvant treatment of early breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None